Evidence map›Paper›PMID 40208314›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2025

PSMA-targeted radioligand therapy with [

Lu Hou, Yanjuan Wang, Haitian Fu, Liping Chen, Chunjing Yu, Xiaoyuan Chen, Jingjing Zhang

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06809426 (Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06809426 nacompletednot on this map

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

TypeinterventionalSponsorAffiliated Hospital of Jiangnan UniversityRan2023 to 2024Enrolled13ConditionsPSMA PET-Positive Castration-Resistant Prostate CancerArms177Lu-LNC1011
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lu HouDepartment of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu, 214000, China.
Yanjuan WangDepartment of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu, 214000, China.
Haitian FuDepartment of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu, 214000, China.
Liping ChenDepartment of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu, 214000, China.
Chunjing YuDepartment of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi, Jiangsu, 214000, China. ycjwxd1978@jiangnan.edu.cn.
Xiaoyuan ChenDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore. chen.shawn@nus.edu.sg.ORCID 0000-0002-9622-0870
Jingjing ZhangDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore. j.zhang@nus.edu.sg.

Funding

National University of Singapore NUHSRO/2020/133/Startup/08
6 · The paper itself

Abstract

backgroundPreclinical studies have shown that the long-acting PSMA-targeting radiopharmaceutical [

methodsEight mCRPC patients who met the inclusion criteria received intravenous treatment with [

resultsHematological toxicity was the primary side effect. In all patients, adverse events (AEs) after [

conclusion[

trial registrationNCT06809426, registration date: 2025-01-23.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantRadioisotopesRadiopharmaceuticalsAgedAged, 80 and overHumansMaleMiddle AgedNeoplasm MetastasisPilot ProjectsTreatment OutcomeAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLutetiumLutetium-177RadioisotopesRadiopharmaceuticals[177Lu]Lu-LNC1011Metastatic castration-resistant prostate cancer (mCRPC)Prostate specific membrane antigen (PSMA)Radioligand therapy

Identifiers

PMID40208314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.